A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Won, Young-Woong | - |
dc.contributor.author | Lee, Hyewon | - |
dc.contributor.author | Eom, Hyeon-Seok | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Suh, Cheolwon | - |
dc.contributor.author | Yoon, Dok Hyun | - |
dc.contributor.author | Hong, Jung Yong | - |
dc.contributor.author | Kang, Hye Jin | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Kim, Won Seog | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Lee, Won-Sik | - |
dc.contributor.author | Chang, Myung Hee | - |
dc.contributor.author | Do, Young Rok | - |
dc.contributor.author | Yi, Jun Ho | - |
dc.contributor.author | Kim, Inho | - |
dc.contributor.author | Won, Jong-Ho | - |
dc.contributor.author | Kim, Kyoungha | - |
dc.contributor.author | Oh, Sung Yong | - |
dc.contributor.author | Jo, Jae-Cheol | - |
dc.date.available | 2020-04-10T02:21:39Z | - |
dc.date.issued | 2020-02 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.issn | 1432-0584 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/38179 | - |
dc.description.abstract | We assessed the efficacy and toxicity of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) combination chemotherapy in patients with refractory or relapsed Hodgkin's lymphoma (HL). This was an open-label, non-randomized, multi-center phase II study. The ESHAOx regimen consisted of intravenous (i.v.) etoposide 40 mg/m(2) on days 1 to 4, i.v. methylprednisolone 500 mg on days 1 to 5, i.v. cytarabine 2 g/m(2) on day 5, and i.v. oxaliplatin 130 mg/m(2) on day 1. Cycles (up to six) were repeated every 3 weeks. In an effort to identify prognostic markers, the serum levels of cytokines including tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP), and vascular endothelial growth factor (VEGF) were measured at the time of study entry. A total of 37 patients were enrolled, and 36 were available for evaluation of tumor response. The overall response rate was 72.2% (26/36) (complete response, 33.3% [12/36]; partial response, 38.9% [14/36]). The median time to progression was 34.9 months (95% confidence interval, 23.1-46.7 months). The most common grade 3 or 4 hematological adverse events were neutropenia (16/37, 43.2%), followed by thrombocytopenia (10/37, 27.0%). Grade 3 or 4 non-hematological adverse events were nausea (3/37, 8.1%), anorexia (2/37, 5.4%), mucositis (1/37, 2.7%), and skin rash (1/37, 2.7%). There were no treatment-related deaths. High levels of TNF-alpha and CRP were significantly associated with poorer overall survival (p = 0.00005 for TNF-alpha, p = 0.0004 for CRP, respectively). The ESHAOx regimen exhibited antitumor activity and an acceptable safety profile in patients with refractory or relapsed HL. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SPRINGER | - |
dc.title | A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s00277-019-03891-9 | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, v.99, no.2, pp 255 - 264 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000505355400001 | - |
dc.identifier.scopusid | 2-s2.0-85077554877 | - |
dc.citation.endPage | 264 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 255 | - |
dc.citation.title | ANNALS OF HEMATOLOGY | - |
dc.citation.volume | 99 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | Etoposide | - |
dc.subject.keywordAuthor | Methylprednisolone | - |
dc.subject.keywordAuthor | Cytarabine | - |
dc.subject.keywordAuthor | Oxaliplatin | - |
dc.subject.keywordAuthor | Hodgkin's lymphoma | - |
dc.subject.keywordPlus | STEM-CELL TRANSPLANTATION | - |
dc.subject.keywordPlus | BRENTUXIMAB VEDOTIN | - |
dc.subject.keywordPlus | SALVAGE THERAPY | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | GEMCITABINE | - |
dc.subject.keywordPlus | DEXAMETHASONE | - |
dc.subject.keywordPlus | REGIMEN | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | VINORELBINE | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.